$BCRX

BioCryst acquired Astria for ~$700M, aiming for $1B rare-disease market. Focus on ORLADEYO, with 60% patient retention. Plans for navenibart and BCX17725. Expects growth in HAE market, pediatric use, and normal C1 inhibitor patients. Maintains profitability.

BioCryst Pharmaceuticals (BCRX) reported its first profit, driven by sales of Orladeyo, and plans to acquire more rare disease treatments. CEO Charlie Gayer aims to grow profits annually without external capital. Orladeyo is projected to generate up to $645M in 2026 sales. The company recently acquired Astria Therapeutics, adding navenibart to its pipeline. BioCryst has $822M in debt and relies heavily on Orladeyo for growth.

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

RBC Capital downgraded BioCryst Pharmaceuticals (BCRX) to 'Sector Perform' and cut its price target to $11, citing competition from Pharvaris's (PHVS) strong HAE therapy data. BCRX shares fell 8%, heading for a fifth straight day of losses. Orladeyo's revenue is expected to drop to $400M-$450M due to competition, though Navenibart's Phase 3 data is awaited in 2027.

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

BioCryst Pharmaceuticals, with a market cap under $5B, reported profitability and plans to expand through acquisitions in the rare disease space. Its FDA-approved drug Orladeyo generated over $2B in sales, with $645M forecasted for 2023. CEO Charlie Gayer aims to leverage the company's financial stability to acquire early-stage assets, targeting smaller peak sales potentials.

BioCryst Pharmaceuticals (BCRX) received Japanese approval for ORLADEYO in pediatric HAE patients aged 2 to under 12. This is the first oral prophylactic therapy for children in Japan, supported by APeX-P trial data. BCRX stock closed at $9.68, up 1.36%, and is trading at $9.72 in pre-market.

BioCryst Pharmaceuticals (BCRX) reported its first full year of profitability in 2025. In Q2 2026, revenue rose 34% to $218.25 million, with $98.47 million operating income and $352.57 million in cash and short-term investments. The company’s HAE drug Orladeyo generated $158.2 million in Q2. Takeda (TAK) is cited as a potential acquirer due to navenibart’s impact on Takhzyro.

BioCryst (BCRX) discussed its Q2 2026 earnings call, citing ORLADEYO revenue of $158.2M, up 10% year-on-year, and total revenue up 45% excluding the European divestiture. Paid therapy rate rose to 84% from 83% a year earlier. The company said it completed enrollment of the ALPHA-ORBIT pivotal study for navenibart, with top-line data expected in Q3 2027, and reported $113.2M non-GAAP operating profit and $350M+ cash.

BioCryst Pharmaceuticals said it will permanently close its Birmingham-area Discovery Center of Excellence and discontinue internal drug discovery. A WARN filing dated Aug. 4 shows layoffs of 47 employees at its Hoover facility starting Oct. 7. The company cut 2026 non-GAAP operating expense guidance to $420 million to $440 million and plans to keep advancing navenibart and BCX17725.